IP Library Granted Patent US 9,029,139
Granted Patent B2
US 9,029,139 · App. 12/730,701 · Granted May 12, 2015

Omentum as a source of stromal/stem cells and medical treatment using stromal/stem cells

Inventors: Makio Iwashima (River Forest, IL); Robert Love (Elmhurst, IL); Rudolf Karl Braun (Madison, WI); Perianna Sethupathi (Wheaton, IL); Katherine Lathrop Knight (Chicago, IL)
Assignee: Loyola University of Chicago
C12N5/0667A61K35/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,029,139
App. No.
12/730,701
Granted
May 12, 2015
Kind
B2
Abstract

Methods for generating and using omentum cells, and particularly stromal cells and/or omentum stem cells, in medical treatments such as tissue repair and regeneration to facilitate healing from traumatic injury to an abdominal organ, and immune modulation treatments such as suppression of immune responses and inflammation and prevention of tissue fibrosis. According to one aspect, a medical procedure is performed on a patient that involves harvesting omental tissue from the patient, and then transferring the omental tissue to an organ of the patient. At least a portion of the harvested omental tissue may be activated prior to transferring the omental tissue to the organ. Alternatively, the transferred omental tissue may comprise non-lymphoid cells isolated from the omentum tissue and obtained by homogenizing at least a portion of the harvested omental tissue. The invention also encompasses a medical procedure comprising the transfer of omental stem cells to a patient, and a procedure comprising in vitro activation of omental stem cells by T cells to enhance immunomodulatory functions of the omental stem cells.

Claims (4)

1. A procedure comprising in vitro activation of omental stem cells by stimulating CD45+ omental cells with activated T cells or IFN-gamma to enhance immunosuppressive functions of the omental stem cells.

2. The procedure according to claim 1 , further comprising in vivo injection of the activated omental stem cells into a patient.

3. The procedure according to claim 2 , wherein the procedure is performed to suppress at least one of inflammation and/or immune responses in the patient.

4. The procedure according to claim 2 , wherein the CD45+ omental cells are directly harvested from the patient.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 5, 2016
From: LOYOLA UNIVERSITY CHICAGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040807/0629 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2010
From: IWASHIMA, MAKIO; LOVE, ROBERT; BRAUN, RUDOLF KARL; SETHUPATHI, PERIANNA; LATHROP KNIGHT, KATHERINE
To: LOYOLA UNIVERSITY CHICAGO
Reel/Frame 024680/0448 →
Continuity (3)
Provisional Application 61163263 · Mar 25, 2009
Provisional Application 61241996 · Sep 14, 2009
Related Publication 20110081321A1 · Apr 7, 2011